ROCKWELL MEDICAL, INC. — Form 10-Q
Filed November 12, 2026 · analyzed by the Periodic Agent
10-Q
▲ Likely positive
significance 92/100
What the filing says
Vantive Limited (Seller) agreed to sell equity interests in HD Group Entities and related assets to Rockwell Medical, Inc. (Buyer) in a transaction dated November 2, 2026. Buyer will pay closing consideration via cash, Buyer Senior Facilities (term loans), and a Buyer Convertible Note, with earnout payments up to $45M based on EBITDA and revenue milestones over 8 years. Transaction includes deferred local business closings in certain jurisdictions pending approvals; some French assets excluded pending employee consultation.
Why this rating
For $28.7M-cap Rockwell, acquiring a standalone dialysis business with earnout potential of $45M (~157% of current market cap) is transformational. Creates material revenue/EBITDA base and acquisition currency via convertible note. Materially alters company trajectory.
Tradability signal
NO TRADE
No trade: positive news with only +0.6% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.74% over 4 hrs, n=27). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $7.15 | +10 min · unknown $7.10 ▼ 0.70% | +30 min · unknown $6.99 ▼ 2.24% | +1 hr · unknown $6.99 ▼ 2.24% | +4 hrs · unknown $7.53 ▲ 5.31% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.